A Randomized, Double-blind, Placebo-controlled Pharmacokinetic and Pharmacodynamic Two Part Cohort Study of JNJ-54452840 in Subjects With Reduced Systolic Function Heart Failure and Elevated Levels of Anti-Beta 1 Adrenergic Receptor Autoantibodies
Status: Withdrawn prior to enrolment
Phase of Trial: Phase II
Latest Information Update: 04 Jun 2014
Price : $35 *
At a glance
- Drugs Mibenratide (Primary)
- Indications Heart failure
- Focus Pharmacodynamics; Pharmacokinetics
- Sponsors Janssen
- 31 Aug 2018 Biomarkers information updated
- 08 Apr 2014 Planned End Date changed from 1 Nov 2014 to 1 Dec 2015 as reported by ClinicalTrials.gov record.
- 08 Apr 2014 Status changed from not yet recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov record.